Keywords: Liver, Liver
Motivation: MRI methods for screening onset of fatty liver disease are lacking owing to the inability to isolate the earliest grades of inflammation, ballooning and fibrosis.
Goal(s): To demonstrate the validity and reproducibility of liver multi-component relaxometry (LiverMap®) in screening onset of liver pathologies at both 1.5T and 3.0T.
Approach: Patient cohorts comprised a validation cohort with 106 biopsy-proven MASLD patients and 16 healthy volunteers, and a reproducibility cohort of 30 volunteers with and without MASLD.
Results: LiverMap® distinguished the onset of liver pathologies with AUROCs above 0.94, a repeatability CoV of 1.7%, and a reproducibility CoV of 3.5%.
Impact: LiverMap® is a new approach to screen and monitor progression of chronic liver conditions in ~10 minutes scan time. In metabolic associated steatohepatitis, LiverMap® reliably distinguishes the onset of five key liver pathologies - fat, iron, inflammation, ballooning and fibrosis.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords